These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 10561976)

  • 1. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer.
    Hou MF; Chen YL; Tseng TF; Lin CM; Chen MS; Huang CJ; Huang YS; Hsieh JS; Huang TJ; Jong SB; Huang YF
    Kaohsiung J Med Sci; 1999 Sep; 15(9):520-8. PubMed ID: 10561976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of serum CA15-3 and CEA in breast cancer.
    Hou MF; Huang TJ; Hsieh JS; Huang YS; Huang CJ; Chan HM; Wang JY; Chen YL; Jong SB; Yang CC
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1995 Dec; 11(12):660-6. PubMed ID: 8551526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
    Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
    Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
    Shao Y; Sun X; He Y; Liu C; Liu H
    PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen.
    Daly L; Ferguson J; Cram GP; Hars V; George SL; McCarty KS; Bast RC
    J Clin Oncol; 1992 Jul; 10(7):1057-65. PubMed ID: 1607912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer.
    Gion M; Mione R; Leon AE; Dittadi R
    Clin Chem; 1999 May; 45(5):630-7. PubMed ID: 10222349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
    Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
    Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
    Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
    Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
    Lumachi F; Basso SM; Brandes AA; Pagano D; Ermani M
    Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases.
    Gion M; Mione R; Leon AE; Lüftner D; Molina R; Possinger K; Robertson JF
    Eur J Cancer; 2001 Feb; 37(3):355-63. PubMed ID: 11239757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
    Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
    Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab.
    Jeschke U; Wiest I; Schumacher AL; Kupka M; Rack B; Stahn R; Karsten U; Mayr D; Friese K; Dian D
    Anticancer Res; 2012 May; 32(5):2185-9. PubMed ID: 22593508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
    Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
    World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.
    Yamamoto N; Nakayama T; Kajita M; Miyake T; Iwamoto T; Kim SJ; Sakai A; Ishihara H; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2012 Feb; 132(1):165-73. PubMed ID: 21594664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer].
    Kaneko Y; Imoto S; Kasakura S
    Rinsho Byori; 1995 Jul; 43(7):696-702. PubMed ID: 7674542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.
    Deprés-Brummer P; Itzhaki M; Bakker PJ; Hoek FJ; Veenhof KH; de Wit R
    J Cancer Res Clin Oncol; 1995; 121(7):419-22. PubMed ID: 7635872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical usefulness of tumor markers in breast cancer].
    Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
    Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.